BMRN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Biomarin Pharmaceutical, Inc.'s quarterly additional paid-in capital increased from Jun. 2013 ($1,864.0 Mil) to Sep. 2013 ($1,926.1 Mil) and increased from Sep. 2013 ($1,926.1 Mil) to Dec. 2013 ($2,059.1 Mil).
Biomarin Pharmaceutical, Inc.'s annual additional paid-in capital increased from Dec. 2011 ($1,197.1 Mil) to Dec. 2012 ($1,561.9 Mil) and increased from Dec. 2012 ($1,561.9 Mil) to Dec. 2013 ($2,059.1 Mil).
Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.
Additional Paid-In Capital is calculated as
|Additional Paid-In Capital||=||(Issue Price||-||Par Value)||*||Shares Outstanding|
* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.
Biomarin Pharmaceutical, Inc. Annual Data
Biomarin Pharmaceutical, Inc. Quarterly Data